We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $515K invested in XTL Biopharmaceuticals in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

14% less capital invested

Capital invested by funds: $596K → $515K (-$81K)

25% less funds holding

Funds holding: 4 → 3 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$3.99K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
NC
1
Noked Capital
Israel
$234K – – –
NI
2
Noked Israel
Israel
$234K – – –
Morgan Stanley
3
Morgan Stanley
New York
$47K +$3.99K +775 +8%
UBS Group
4
UBS Group
Switzerland
– -$2K -306 Closed

XTLB Hedge Fund Activity: Q1 2020 in Review

3 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2020, worth a combined $515K — down 14% from $596K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $3.99K. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2020, down from 4 in Q4 2019.
  • Funds reported $515K of XTL Biopharmaceuticals stock for Q1 2020, down 14% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q1 2020 and 1 closed out, a net change of -1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q1 2020 was Morgan Stanley, an estimated $3.99K added.
  • The largest XTL Biopharmaceuticals seller in Q1 2020 was UBS Group, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2020.